Now available LUNSUMIO™

LUNSUMIO™ (mosunetuzumab-axgb) is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Please see full prescribing information here.